Mounjaro 15 mg: the highest licensed dose explained

What the SURMOUNT-1 trial tells us about 15 mg

The SURMOUNT-1 trial, whose results appeared in the New England Journal of Medicine, randomised 2,539 adults with obesity or overweight and at least one weight-related condition to tirzepatide or placebo across 72 weeks. Three doses were tested: 5 mg, 10 mg, and 15 mg. At 15 mg, participants lost an average of roughly 20–21% of their body weight; some analyses placed the figure slightly higher at around 22.5%. No other dose reached that level, and the gap between 5 mg and 15 mg was substantial, the trial is part of why NICE's appraisal of tirzepatide (TA1026) described the evidence base as robust enough to recommend it for NHS use.

These are group averages from a controlled clinical setting. Individual responses vary, and the trial does not predict what any one person will lose. What the data does confirm is that tirzepatide's dual action on GIP and GLP-1 receptors (slowing gastric emptying and increasing satiety) appears to scale meaningfully with dose up to the maximum.

For a sense of how Mounjaro compares across its full strength range, the dose-by-dose evidence is worth reviewing alongside your prescriber's guidance.

Getting to 15 mg: the titration path and why it matters

Treatment begins at 2.5 mg, a strength whose job is to settle the body into the medicine rather than drive weight loss. Each step up takes at minimum four weeks, meaning 15 mg cannot be reached before approximately week 20. The sequence runs 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, then 15 mg. For a fuller look at how the full Mounjaro dose schedule works, that page covers each rung in detail.

A prescriber decides at every review whether an increase is appropriate. If side effects are poorly tolerated at a given dose, the increase is delayed or not made, some people find their optimal dose is 10 mg or 12.5 mg rather than the maximum. Reaching 15 mg is never automatic; it follows clinical evidence that the previous dose has been tolerated and that continuing to titrate is in the patient's interest.

On the practical side: each Mounjaro KwikPen contains four doses, so a 15 mg pen covers one calendar month. Store it in the fridge door between doses, the pen is already there, where it is easy to remember on injection day. Details on the 15 mg Mounjaro KwikPen itself, including what to check before use, are covered separately.

Side effects at the highest dose

Gastrointestinal effects (nausea, loose stools, constipation, indigestion) are the most common across all Mounjaro doses and tend to be most noticeable after a new dose is started. At 15 mg there is some evidence that GI effects can be slightly more pronounced than at lower strengths, though many people report that their system adjusted to earlier doses and find the step to 15 mg manageable. Effects typically ease within the first two weeks at a new dose.

More detailed information on what to expect is on the Mounjaro 15 mg side effects page, including the symptoms that warrant prompt medical attention. The MHRA also maintains a Yellow Card reporting scheme for anyone who experiences a suspected side effect, it is worth knowing about before you start treatment, not just if something goes wrong.

Tirzepatide carries a Black Triangle (▼) designation, meaning it is subject to additional monitoring by the MHRA. This is standard for newer medicines and does not indicate it is less safe than established treatments.

Who is a candidate for 15 mg, and what comes next

Under its UK licence, tirzepatide is approved for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Reaching the 15 mg dose is a decision made within that clinical framework, not a target every patient needs to pursue.

NICE's guidance (TA1026) notes that if a patient achieves less than 5% weight loss after six months at the highest tolerated dose, continuing treatment should be reviewed. That review is a clinical conversation, not an automatic stop. For those also managing type 2 diabetes, the maintenance dose picture in diabetes involves some additional considerations worth exploring.

If you are considering starting treatment or are already on a lower dose and wondering whether 15 mg is the right direction, the free consultation at nume connects you with a GPhC-registered Independent Prescriber who reviews your case the same day. Pricing context, including what a private prescription involves, is covered on the treatment overview. Cost is a reasonable thing to think about; the Eli Lilly UK price change from September 2025 has affected what private providers pay for supply, and that context is worth understanding before you commit.